PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

已收盘 05-01 16:00:00 EDT

15.55

+0.04

+0.26%

盘后15.44

-0.11-0.71%

16:20 EDT

最高15.79	最低15.43	成交量126.75万
今开15.64	昨收15.51	日振幅2.32%
总市值14.16亿	流通市值12.72亿	总股本9,108万
成交额1,978万	换手率1.55%	流通股本8,179万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":15.55,"timestamp":1746129600000,"preClose":15.51,"halted":0,"volume":1267488,"hourTrading":{"tag":"盘后","latestPrice":15.44,"preClose":15.55,"latestTime":"16:20 EDT","volume":41664,"amount":647836.96,"timestamp":1746130800864},"delay":0,"floatShares":81793630,"shares":91084454,"eps":-0.591956,"marketStatus":"已收盘","change":0.04,"latestTime":"05-01 16:00:00 EDT","open":15.64,"high":15.79,"low":15.43,"amount":19781958.993408,"amplitude":0.023211,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.591956,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746172800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":15.51,"postHourTrading":{"tag":"盘后","latestPrice":15.44,"preClose":15.55,"latestTime":"16:20 EDT","volume":41664,"amount":647836.96,"timestamp":1746130800864},"volumeRatio":0.979494,"impliedVol":0.4598,"impliedVolPercentile":0.316},"requestUrl":"/m/hq/s/PD/wiki","defaultTab":"wiki","newsList":[{"id":"2530549955","title":"康方生物依沃西获批用于PD-L1阳性肺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530549955","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530549955?lang=zh_cn&edition=full","pubTime":"2025-04-28 09:32","pubTimestamp":1745803955,"startTime":"0","endTime":"0","summary":"4月27日，康方生物（09926）发布公告，宣布其自主研发的双特异性抗体依达方?（依沃西，PD-1/VEGF）获得中国国家药品监督管理局（NMPA）批准，用于一线治疗PD-L1阳性非小细胞肺癌（NSCLC）。这是依沃西获得的第二个适应症，标志着中国患者能够率先使用全球最优治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504283390722024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PD","BK4023","09926","BK1574","IE00BPRC5H50.USD","LU0348783233.USD","LU1169589451.USD","LU1169590202.USD","IE00B543WZ88.USD","LU1720050803.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU2488822045.USD","BK1161","LU0417516571.SGD","LU0348784397.USD"],"gpt_icon":0},{"id":"2530379034","title":"康方生物(09926.HK)：依达方®(依沃西，PD-1/VEGF)第二个适应症上市申请获得NMPA批准，用于一线治疗PD-L1阳性NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530379034","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530379034?lang=zh_cn&edition=full","pubTime":"2025-04-27 19:58","pubTimestamp":1745755137,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨康方生物宣布，由公司自主研发的全球首创双特异性抗体依达方单药用于PD-L1阳性的表皮生长因子受体基因突变阴性和间变性淋巴瘤激酶阴性的局部晚期或转移性非小细胞肺癌的一线治疗的新药上市申请，已获得中国国家药品监督管理局批准上市。这是依沃西获批上市的第二个适应症，让中国患者‘‘率先用上全球最优治疗方案’’成为现实。依沃西是全球首个在头对头帕博利珠单抗的III期临床研究中获得显著阳性结果的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27195849930778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU0417516571.SGD","PD","LU1169590202.USD","09926","LU1720050803.USD","BK1574","IE00BPRC5H50.USD","LU1794554557.SGD","BK4023","LU0348784397.USD","BK1161","LU1169589451.USD"],"gpt_icon":1},{"id":"2530916455","title":"【康方生物(09926.HK)安尼可®（派安普利，PD -1）获美国食品药品监督管理局批准 两项适应症用于治疗晚期鼻咽癌】康方生物(09926.HK)发布公告，安尼可®(派安普利，PD-1)已获得美国食品药品监督管理局(FDA)批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530916455","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530916455?lang=zh_cn&edition=full","pubTime":"2025-04-25 08:18","pubTimestamp":1745540328,"startTime":"0","endTime":"0","summary":"康方生物(09926.HK)发布公告，安尼可®(派安普利，PD-1)已获得美国食品药品监督管理局(FDA)批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25081849860793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BPRC5H50.USD","LU0417516571.SGD","LU0348784397.USD","LU1169590202.USD","LU2488822045.USD","PD","BK1574","IE00B5MMRT66.SGD","BK4023","LU1720050803.USD","IE00B543WZ88.USD","09926","LU1794554557.SGD","LU0348783233.USD","159839","BK1161","LU1169589451.USD"],"gpt_icon":0},{"id":"2530191575","title":"康方生物(09926)安尼可®（派安普利，PD -1）获美国食品药品监督管理局批准 两项适应症用于治疗晚期鼻咽癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2530191575","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530191575?lang=zh_cn&edition=full","pubTime":"2025-04-25 08:13","pubTimestamp":1745539980,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，安尼可已获得美国食品药品监督管理局批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。派安普利本次在美国获批上市，为全球的晚期鼻咽癌患者提供了免疫治疗新选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","LU1169589451.USD","BK1161","LU1794554557.SGD","LU2488822045.USD","PD","IE00B5MMRT66.SGD","LU1720050803.USD","BK1574","IE00B543WZ88.USD","LU0348784397.USD","LU0417516571.SGD","09926","IE00BPRC5H50.USD","BK4023","LU1169590202.USD"],"gpt_icon":0},{"id":"2529640246","title":"港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2529640246","media":"智通财经","labels":["conferences","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529640246?lang=zh_cn&edition=full","pubTime":"2025-04-24 14:37","pubTimestamp":1745476662,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343在胰腺癌研究方面均有口头报告。本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","BK1589","BK4023","LU1969619763.USD","LU2488822045.USD","PD","BK1583","LU2328871848.SGD","LU1169589451.USD","BK1161","LU1169590202.USD"],"gpt_icon":0},{"id":"2529617317","title":"港股异动 | 基石药业-B(02616)最高涨超7% 三抗CS2009（PD-1/VEGF/CTLA-4）即将在AACR更新更多数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2529617317","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529617317?lang=zh_cn&edition=full","pubTime":"2025-04-24 11:35","pubTimestamp":1745465743,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B早盘最高涨超7%，截至发稿，涨2.41%，报2.97港元，成交额1672.07万港元。基石药业5款自主研发创新药物的最新临床前研究成果将同时亮相这一国际顶级学术舞台，包括三抗CS2009、双抗CS2011及出自公司自有抗体偶联药物平台的三款创新ADC分子CS5006、CS5007与CS5005。其中90%用于与集团“管线2.0”中的资产，尤其是CS5001，以及CS2009有关的进一步研发；余下净额于适当时用于其他一般公司用途。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","02616","PD","BK1574","LU1169589451.USD","BK1161","LU1169590202.USD"],"gpt_icon":0},{"id":"2529693739","title":"荣获七项ASCO口头报告：信达生物IBI363（PD-1/IL-2α-bias）领衔多款管线亮相美国临床肿瘤学会2025年大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2529693739","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529693739?lang=zh_cn&edition=full","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。信达生物制药集团高级副总裁周辉博士表示：\"很高兴在本次ASCO大会上，IBI363开发的第一批三大适应症黑色素瘤、肠癌、非小细胞肺癌的临床研究均被接收为口头报告，代表了下一代PD-1双抗肿瘤免疫疗法引起了全球的广泛关注。同时IBI343胰腺癌研究继去年12月ESMO Asia口头报告之后，再次以口头报告登上ASCO舞台。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4671176_ZH71176_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1969619763.USD","LU2488822045.USD","BK4139","01801","LU1169590202.USD","BK1161","BK4023","BK1583","IVBIY","LU2328871848.SGD","LU1169589451.USD","BK1589","PD"],"gpt_icon":1},{"id":"2529687522","title":"Pagerduty, Inc.盘中异动 早盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529687522","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529687522?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:40","pubTimestamp":1745415624,"startTime":"0","endTime":"0","summary":"北京时间2025年04月23日21时40分，Pagerduty, Inc.股票出现异动，股价大幅上涨5.08%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为3.35%。其相关个股中，Pegasystems Inc.、Apptech Payments Corp C/Wts 04/01/2027 、Triller Group Inc C/Wts 15/03/2027 涨幅较大，Femto Technologies Inc.、Microalgo, Inc.、Oblong Inc.较为活跃，换手率分别为15.88%、12.57%、11.91%，振幅较大的相关个股有Triller Group Inc C/Wts 15/03/2027 、Femto Technologies Inc.、百家云，振幅分别为18.07%、15.28%、13.36%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423214025aa2c7890&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423214025aa2c7890&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD","BK4023","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2529952490","title":"又一次“头对头”胜出！康方生物双抗药物疗效“击败”百济神州PD-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2529952490","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529952490?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:41","pubTimestamp":1745397660,"startTime":"0","endTime":"0","summary":"早间，康方生物宣布，公司双抗药物依沃西单抗又一次在头对头试验中战胜了PD-1，这次挑战的对象是百济神州的替雷利珠单抗。4月23日，百济神州A股股价下跌1.42%。依沃西是康方生物自主研发的、全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物。康方生物的依沃西选择对标的这两款PD-1单抗，都有一定的代表性。百济神州的替雷利珠单抗在中国，已取得领先的PD-1市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042316430794df5305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042316430794df5305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","688235","09926","LU1169590202.USD","06160","BK4139","PD","LU1169589451.USD","ONC"],"gpt_icon":0},{"id":"2529502592","title":"康方生物在一项临床三期试验中赢了百济神州的PD-1抗体联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502592","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529502592?lang=zh_cn&edition=full","pubTime":"2025-04-23 09:38","pubTimestamp":1745372280,"startTime":"0","endTime":"0","summary":"康方生物双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州的替雷利珠单抗。在此次头对头试验中，依沃西联合化疗把替雷利珠单抗联合化疗作为对照组。康方生物表示，HARMONi-6临床试验共入组532例受试者，中央型鳞癌占比约为63%，与真实世界患者分布一致。与治疗相关的严重不良反应发生率以及三级及以上出血事件发生率与对照组相似。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4023","LU1169589451.USD","LU1169590202.USD","PD"],"gpt_icon":0},{"id":"2529594594","title":"港股异动 | 康方生物(09926)涨超13%创历史新高 康方PD-1/VEGF双抗首次战胜PD-1+化疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2529594594","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529594594?lang=zh_cn&edition=full","pubTime":"2025-04-23 09:34","pubTimestamp":1745372059,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超13%，高见99.9港元，创历史新高。截至发稿，涨11.03%，报98.1港元，成交额6.79亿港元。消息面上，4月23日，康方生物欣喜地宣布，全球首创双特异性抗体新药依沃西单抗注射液联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的注册性III期临床研究，经独立数据监察委员会评估的预先设定的期中分析显示强阳性结果。本研究详细数据将在今年相关国际术会议上公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1794554557.SGD","PD","09926","LU0348784397.USD","LU1720050803.USD","BK4023","LU0417516571.SGD","LU0348783233.USD","LU1169589451.USD","LU2488822045.USD","LU1169590202.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1574"],"gpt_icon":0},{"id":"2529312022","title":"百时美施贵宝（BMY.US）PD-1抑制剂在中国获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2529312022","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529312022?lang=zh_cn&edition=full","pubTime":"2025-04-22 14:41","pubTimestamp":1745304064,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月22日，百时美施贵宝宣布，PD-1抑制剂欧狄沃获得中国NMPA批准新增适应症。此次获批后，纳武利尤单抗已在中国获批13项适应症，其中包括4项早期肿瘤适应症，包括围术期、新辅助和辅助治疗，覆盖肺癌、食管癌、尿路上皮癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE0002141913.USD","LU1093756168.USD","LU1718418525.SGD","LU1169589451.USD","LU0114720955.EUR","LU1868836914.USD","LU0868494617.USD","LU0096364046.USD","LU1670711123.USD","LU2125154935.USD","BK4588","LU1430594728.SGD","IE00BJJMRZ35.SGD","LU0225284248.USD","BK4559","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585","LU1571399168.USD","BK4581","IE00BFTCPJ56.SGD","LU1169590202.USD","IE00BFXG1179.USD","LU2242646821.SGD","BK4534","IE00BSNM7G36.USD","LU1989771016.USD","LU1585245621.USD","LU1323610961.USD","LU0456855351.SGD","PD","LU1074936037.SGD","LU1868836591.USD","LU2242652126.USD","BMY","LU0321505439.SGD","LU0985481810.HKD","LU1291159041.SGD","BK4532","LU1261432733.SGD","LU1032466523.USD","LU1670710588.SGD","LU2360032135.SGD","LU1093756325.SGD","LU0321505868.SGD","LU0306807586.USD","LU0237698245.USD","IE0009355771.USD","LU0882574055.USD","LU1868836757.USD"],"gpt_icon":0},{"id":"2529436787","title":"港股异动 | 三生制药(01530)涨超3% 抗VEGF/PD-1双特异性抗体获国家药监局突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2529436787","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529436787?lang=zh_cn&edition=full","pubTime":"2025-04-22 09:46","pubTimestamp":1745286407,"startTime":"0","endTime":"0","summary":"消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。据介绍，707注射液是三生制药基于CLF2专利平台自主开发的靶向VEGF/PD-1双特异性抗体，目前正于中国开展多项临床研究，其中一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌已获国家药监局药品审评中心批准开展III期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","LU1169590202.USD","BK1593","BK4023","BK1161","BK1583","01530","LU1169589451.USD"],"gpt_icon":0},{"id":"2529824524","title":"恒瑞医药：子公司收到药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2529824524","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529824524?lang=zh_cn&edition=full","pubTime":"2025-04-21 16:57","pubTimestamp":1745225864,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0012","LU0405327148.USD","LU1169590202.USD","LU1169589451.USD","BK1515","BK1576","LU2328871848.SGD","LU1328615791.USD","BK0239","BK1141","BK0183","09939","LU0405327494.USD","LU1969619763.USD","LU2488822045.USD","BK0196","BK1583","BK0188","399441","LU1064130708.USD","BK0028","PD","LU2148510915.USD","600276","LU1064131003.USD","161726","159938","03347","BK1161","BK4023","BK0060","BK1574"],"gpt_icon":0},{"id":"2528422171","title":"大摩：维持PagerDuty评级，由持股观望调整至持股观望评级, 目标价由20.00美元调整至17.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2528422171","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528422171?lang=zh_cn&edition=full","pubTime":"2025-04-17 00:22","pubTimestamp":1744820565,"startTime":"0","endTime":"0","summary":"大摩：维持PagerDuty(PD.US)评级，由持股观望调整至持股观望评级, 目标价由20.00美元调整至17.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417002540973a22b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250417002540973a22b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PD"],"gpt_icon":0},{"id":"2518980763","title":"辉瑞(PFE.US)PD-L1靶向ADC新药在华获批临床 拟治疗晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2518980763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518980763?lang=zh_cn&edition=full","pubTime":"2025-03-11 14:10","pubTimestamp":1741673430,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月10日，中国国家药监局药品审评中心官网最新公示，辉瑞公司旗下Seagen申报的1类新药PF-08046054获得临床试验默示许可，拟开发治疗转移性或不可切除的晚期实体瘤。公开资料显示，这是辉瑞在研的一款潜在“first-in-class”PD-L1靶向抗体偶联药物。截图来源：CDE官网根据辉瑞公开资料介绍，PF-08046054是一款靶向PD-L1的ADC，由抗PD-L1抗体、连接子和微管破坏剂MMAE组成，可通过直接细胞毒性、旁观者杀伤、免疫原性细胞死亡来发挥抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1260252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0321505439.SGD","LU1169589451.USD","BK4534","ADC","IE0002270589.USD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0225771236.USD","LU1057294990.SGD","LU0868494617.USD","LU0058720904.USD","LU0225284248.USD","BK4585","LU1066051498.USD","PD","SG9999003800.SGD","BK4231","BK4550","LU1883839398.USD","SG9999013999.USD","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0985481810.HKD","LU0306807586.USD","BK4599","LU0306806265.USD","LU0122379950.USD","BK4007","LU0289739699.SGD","BK4588","LU1894683348.USD","BK4592","LU1894683264.USD","BK4080","BK4533","SG9999001176.SGD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU1023059063.AUD","LU0170899867.USD","BK4023","PFE","SG9999001176.USD","LU0234572021.USD","SG9999002224.SGD","LU0321505868.SGD","BK4581","SG9999011175.SGD","LU1169590202.USD"],"gpt_icon":1},{"id":"2518248700","title":"阿斯利康PD-L1肿瘤药在中国获批第四项适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2518248700","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518248700?lang=zh_cn&edition=full","pubTime":"2025-03-10 18:01","pubTimestamp":1741600887,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4588","BK4568","PD","LU1169590202.USD","BK4008","BK4023","LU0320765992.SGD","LU2456880835.USD","BK4585","LU2462157665.USD","LU1829250122.USD","AZN","LU2417539215.USD","LU2236285917.USD","BK4500","LU0889565916.HKD","BK4007","LU1169589451.USD","LU0109394709.USD","ALK"],"gpt_icon":0},{"id":"2517438513","title":"阿斯利康(AZN.US)胃癌围手术期PD-L1联合疗法优于标准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438513","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517438513?lang=zh_cn&edition=full","pubTime":"2025-03-07 21:20","pubTimestamp":1741353606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月7日，阿斯利康宣布III期MATTERHORN研究结果显示，Imfinzi联合标准治疗FLOT化疗作为可切除的早期和局部晚期的胃癌和胃食管交界处癌患者围手术期治疗方案，主要终点无事件生存期具有统计学意义和临床意义的改善。MATTERHORN是首个证明免疫疗法联合治疗优于标准治疗的全球随机III期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AZN","BK4007","BK4568","LU1169589451.USD","LU1169590202.USD","LU1829250122.USD","LU0889565916.HKD","LU2456880835.USD","LU2417539215.USD","LU2462157665.USD","PD","LU0109394709.USD","LU0320765992.SGD","BK4585","LU2236285917.USD","BK4588","BK4023"],"gpt_icon":0},{"id":"2517122840","title":"【康方生物：依沃西头对头帕博利珠单抗Ⅲ期临床研究结果在《柳叶刀》发表】 近日，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西单药对比帕博利珠单抗单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性Ⅲ期临床研究(HARMONi-2/AK112-303）的研究数据，在国际顶级医学期刊《柳叶刀》发表。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517122840","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517122840?lang=zh_cn&edition=full","pubTime":"2025-03-07 13:57","pubTimestamp":1741327045,"startTime":"0","endTime":"0","summary":"近日，康方生物自主研发的全球首创PD-1/VEGF双特异性抗体新药依沃西单药对比帕博利珠单抗单药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的注册性Ⅲ期临床研究(HARMONi-2/AK112-303）的研究数据，在国际顶级医学期刊《柳叶刀》发表。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/07135748586398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00B5MMRT66.SGD","BK4023","09926","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU1720050803.USD","LU0417516571.SGD","LU0348784397.USD","LU1169589451.USD","LU1169590202.USD","PD","LU1794554557.SGD","BK1161","LU0348783233.USD","BK1574","LU2488822045.USD"],"gpt_icon":0},{"id":"2517497936","title":"【基石药业-B(02616.HK)在澳大利亚递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤的临床试验申请】基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517497936?lang=zh_cn&edition=full","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4023","BK4080","BK1161","BK4231","LU1169589451.USD","03347","BK1583","PD","BK1141","BK1576","LU1169590202.USD","02616","BK1574","ADC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.1511},{"period":"3month","weight":-0.1593},{"period":"6month","weight":-0.1603},{"period":"1year","weight":-0.2229},{"period":"ytd","weight":-0.1506}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0835},{"period":"6month","weight":-0.0289},{"period":"1year","weight":0.1047},{"period":"ytd","weight":-0.0538}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.045759},{"month":2,"riseRate":0.5,"avgChangeRate":-0.032478},{"month":3,"riseRate":0.5,"avgChangeRate":-0.018297},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.049825},{"month":5,"riseRate":0.333333,"avgChangeRate":0.0049},{"month":6,"riseRate":0.666667,"avgChangeRate":0.013501},{"month":7,"riseRate":0.5,"avgChangeRate":0.011648},{"month":8,"riseRate":0.5,"avgChangeRate":-0.00702},{"month":9,"riseRate":0,"avgChangeRate":-0.131039},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.037852},{"month":11,"riseRate":0.666667,"avgChangeRate":0.066825},{"month":12,"riseRate":0.5,"avgChangeRate":0.034253}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}